Roland F. Staack

Saarland University

2 papers in the library · 318 citations · publishing 2003-2004

Papers

Screening for and validated quantification of amphetamines and of amphetamine‐ and piperazine‐derived designer drugs in human blood plasma by gas chromatography/mass spectrometry

Journal of Mass Spectrometry June 1, 2003 Frank T. Peters, Simone Schaëfer, Roland F. Staack et al. 171 citations

A method was developed to screen for and simultaneously quantify classical stimulants (amphetamine, methamphetamine, ethylamphetamine, MDA, MDMA, MDEA, BDB, MBDB) and newer designer drugs (4-methylthioamphetamine, p-methoxyamphetamine, p-methoxymethamphetamine, and several piperazine derivatives) along with two metabolites in human blood plasma. The technique uses gas chromatography/mass spectrometry with selected-ion monitoring after solid-phase extraction and derivatization. The method was linear from 5 to 1000 µg/L for all analytes, with a limit of quantification of 5 µg/L. Accuracy and precision met required limits except for MDBP. The assay was validated and applicable for confirming immunoassay results positive for amphetamines or ecstasy-type designer drugs.

DOI: 10.1002/jms.483 Ecstasy MDMA Designer drug Chemistry +11

Chemistry, Pharmacology, Toxicology, and Hepatic Metabolism of Designer Drugs of the Amphetamine (Ecstasy), Piperazine, and Pyrrolidinophenone Types

Therapeutic Drug Monitoring March 19, 2004 Hans H. Maurer, Thomas Kræmer, Dietmar Springer et al. 147 citations

Designer drugs such as MDMA, MDEA, MDA, and various piperazine and pyrrolidinophenone compounds, often used as rave drugs, produce euphoria, energy, and sociability. Despite their reputation as safe, studies in rats and primates along with human epidemiological investigations indicate potential risks, including serotonin syndrome, liver toxicity, neurotoxicity, and psychological problems. Metabolites may contribute to some toxic effects, so understanding metabolism is crucial for risk assessment. The enzyme CYP2D6, which is polymorphically expressed, catalyzes the major metabolic steps of piperazine- and pyrrolidinophenone-derived designer drugs, though it remains unclear whether this genetic polymorphism is clinically relevant.

DOI: 10.1097/00007691-200404000-00007 Ecstasy MDMA Mescaline Designer drug +6